

CytoTools subsidiary CytoPharma GmbH reported first successful animal models in the field of oncology with the new patented active substance candidates

- **Successful animal models in the oncology field of indications with new patented active substance molecules**
- **Expansion of the successful animal studies for the preparation of the first human trials**
- **The possibility of a fundamentally new cancer therapy confirmed**

Darmstadt, 16th December 2019 – The CytoTools AG, a technology holding company (ISIN DE000A0KFRJ1), announces that its subsidiary, CytoPharma GmbH, for the first time, has successfully tested the new, patented active substance candidates in the field of oncology in animal models. After already demonstrating their exceptional efficacy in cultures (in vitro) of various human carcinoma cells, the new active substance molecules have now shown that, when applied to organisms (in vivo), they also are effective in killing cancer cells. In these first trials with animal models, concentrations and application forms of the new active substances were examined. Here, exemplary examinations were carried out on three different types of human cancer (melanoma, breast cancer and pancreas). A clear reduction in the volume of cancer cells was measurable in all indications, whereby the best results were achieved in the breast cancer indication. After these first successes, the examinations will be extended to further patented active substances, concentrations and application forms.

The directors of the CytoTools AG, Dr. Mark-Andre Freyberg and Dr. Dirk Kaiser, summarized the successes as follows: „For us, the results of the animal model trials on human cancer cells in the oncology indication are the starting signal for further large scale trials. The efficacy in animal models provides the proof that the active substance candidates, patented this year, are also active in organisms. With this result, an important hurdle has been cleared in the successful further new drug development. “

In case further data point in the same direction, the successful animal model trials will provide the prerequisites for first human clinical trials. For these, at an early stage, we intend to engage a development partner.



With the successful formation of the oncological pipeline, as well as the great potential of the ready-to-market dermatological products from its subsidiary DermaTools Biotech GmbH, in future, the CytoTools AG now has a second mainstay with considerable chances for a fundamentally new and innovative cancer therapy, based on the activation of programmed cell death (apoptosis). This means that the chance arises of putting the evaluation of CytoTools on a completely new footing.

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Vorstand
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

UBJ. GmbH
Ingo Janssen
Haus der Wirtschaft
Kapstadtring 10
D-22297 Hamburg
Tel.: +49-40-6378-5410
Fax: +49-40 6378-5423
E-Mail: ir@ubj.de

This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

About CytoTools

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (62%) and CytoPharma GmbH (50%).